September 2022 • PharmaTimes Magazine • 34-35
// YOUR MOVES //
Your Moves
Movers of the Month
Steve Allin
Lee Patterson
After nearly 25 years at Charnwood Molecular – a UK-based preclinical discovery CRO serving the global pharmaceutical and biotechnology market – Professor Steve Allin announced that he would be stepping down as CEO and would be succeeded by Lee Patterson.
From founding the business as a Loughborough University spin-out, alongside Professor Phil Page in 1998, Steve has been at the forefront of the company’s growth and development.
Steve, who will remain as an investor and board advisor explained: “Now is the right time for me personally, to hand over the reins to Lee who will be instrumental in driving the company forward over the next few years. I'd like to thank all the Charnwood Molecular team, past and present, for their fantastic contributions and constant support over the years.”
Lee Patterson joins Charnwood Molecular with extensive experience gained across the drug discovery sector. Most recently this included senior executive leadership roles at Concept Life Sciences and Covance. Lee also brings a scientific background in pathological and biomedical sciences.
Revolution Medicines – a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers – has announced the appointment of Doctor Lorence Kim to its board of directors.
Lorence has made significant contributions across the biotechnology and financial industries during his career at Moderna and Goldman Sachs. He has extensive operational expertise and an extraordinary track record in raising capital for high-growth healthcare companies.
He is known particularly for his time as Chief Financial Officer of Moderna, where over six years he was instrumental in raising $4.4 billion in capital to support the company’s platform efforts in mRNA therapeutics and the development of its pipeline of more than 20 drug candidates spanning oncology and other therapeutic areas.
Before joining Moderna, Lorence had a highly productive 14-year career at Goldman Sachs, where he advised numerous companies as a Managing Director and co-head of biotechnology investment banking.
Ixaka, an integrated cell and gene therapy company focused on boosting the natural power of the body to cure disease, has announced the appointment of Dr Karen Miller as Chief Scientific Officer.
Karen brings more than 30 years of experience in the biotech and pharma industry, leading drug discovery, preclinical and clinical development teams in a wide range of indications and multiple modalities. Karen’s track record has been built around her extensive leadership and advisory experience, developing strong cross-functional relationships to enable rapid pipeline progression.
Most recently, Karen was Senior Vice President, Pipeline Research, at Adaptimmune PLC a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products.
The Creative Engagement Group has appointed experienced healthcare and digital strategist Tom Griffiths.
To further bolster its strategic capabilities, The Creative Engagement Group has hired Tom as Strategy and Planning Director to help the communications group apply connected strategic planning across its divisions and capabilities.
He joins from Saatchi & Saatchi Wellness where he was an Integrated Strategy Director and before that Digital Strategy Director in the greyhealth group, part of WPP Health & Wellness.
He joins a multidisciplined team of behavioural scientists, researchers, insight consultants and learning experts who help combine the diverse expertise of the group to create experiences that inspire lasting change for a wide range of blue-chip clients.
With specific expertise in healthcare and the application of omnichannel planning, Tom has driven the creative and brand strategy for the likes of Bayer, Pfizer, Sanofi, Galderma and GSK.
Fusion Antibodies has confirmed the appointment of Dr Adrian Kinkaid as Chief Executive Officer. His appointment follows an extensive formal search process.
Adrian has 25 years’ experience in life sciences and biotherapeutics industries. He joins Fusion from Vortex, a biotech group focused on technology for the isolation of high-quality circulating tumour cells. As CEO of Vortex, Adrian led the company’s development, including management of its business units.
Prior to joining Vortex, Adrian worked as CEO at several antibody-based diagnostics companies including BioFab and Lumabs BV. He was also Chief Commercial Officer at Promexus Ltd.
Current Global has announced that Jess Hinton and Adeva Merela have joined its UK healthcare team as Account Director and a Senior Associate respectively.
The new hires come at a time of strong momentum for the firm in the UK. Based in London, Jess joins Current Global from MHP and has over five years of agency experience in the healthcare sector, delivering programmes across the pharmaceutical, health technology and advocacy sectors at UK, European and global levels.
Adeva has joined from IPG sister agency DNA, where she was supporting on medical communications and PR programmes.
Current Global UK’s health team delivers high-impact communications and advocacy that addresses key issues at the intersection of innovation, society and business reaching a wide range of stakeholders.
Hanover has announced that former NHS England National Director of Strategy, Primary Care and Community Services, Ian Dodge has joined Hanover as a Senior Adviser.
Ian was part of the NHS England Board and Executive leadership team from 2014 to 2022. He will support clients to understand the NHS environment as the health system changes to a new structure and seeks to adopt new innovative practices, technologies and therapies.
He led NHS England’s approach to the current NHS reforms and reorganisation, and has led the organisation’s innovation and transformation work amongst other responsibilities during his time at NHS England.
Ian joins a suite of Hanover senior advisers focused on market access and health system innovation including former payers, regulators, industry execs and health system managers in the UK and European and international markets.
Newcastle-based healthcare communications agency Onyx Health has expanded its growing digital content team with the double appointment of Hope Johnston as Digital Content Manager and Jordan Carr as Social Media Executive.
Onyx Health's new digital content specialist Hope grew up in South Tyneside and holds a Business and Marketing Management degree from Sunderland University. She joins the Onyx Health team from Gateshead-based agency, Mediaworks, where she was a Content Strategist, working across multiple client accounts regionally and nationally.
Prior to this, Hope worked for leading parent and baby brand, Tommee Tippee, as a Digital Marketing Manager and for Hebburn Sports Club as its Marketing Manager.
A Newcastle native, Jordan started his career as a Digital Media Apprentice at Newcastle University Students Union, before progressing to become a Marketing Assistant. In this role, he was responsible for the Student Union's social media and creative content, which incorporated elements of video and creative design.
Third Harmonic Bio has announced the appointment of Thomas Soloway to its Board of Directors. Thomas brings more than 25 years of experience in the life sciences industry, with senior roles in strategy, operations, corporate finance and venture capital.
He is currently Chief Executive Officer of T-knife Therapeutics. Before joining T-knife, he was at Audentes Therapeutics – most recently serving as Executive Vice President and Chief Operating Officer.
Previously, Thomas served as Senior Vice President at Ascendis Pharma and, prior to that, he co-founded Transcept Pharmaceuticals.
Amarin has expanded its European presence by appointing two new members to its European Leadership Team, who will be responsible for driving forward the company’s expansion plans in the Nordics, Spain and Portugal.
The dual appointments of Henrik Asmussen as General Manager of Mid-Europe & the Nordics, and Salvador Lopez as General Manager for Spain and Portugal, mark an important milestone in the next phase of Amarin’s European growth.
Henrik brings over 20 years of biopharmaceutical industry experience to the Amarin team. He joins the company from Amgen, where he served as General Manager of Switzerland after spearheading the European launch of its cardiovascular treatment Repatha.
Salvador joins from Mundipharma where he several senior leadership roles, including General Manager of Portugal, Switzerland and Austria, before becoming General Manager for its Mid-EU cluster and part of the company’s European Leadership Team.
Vaccentis – a clinical-stage Swiss biopharmaceutical company developing patient-specific medicines – has appointed Martin Munte as CEO.
A veteran leader in biotech and pharma, he has extensive executive experience at Amgen, AstraZeneca and Roche.
Martin held a series of senior roles at Amgen for 12 years – most recently as External Access Engagement Lead Europe. He previously held management positions at both AstraZeneca and Roche. He also has strong expertise as a leader in general management, sales and marketing, policy, access, regulatory and business development.
The appointment further strengthens Vaccentis’ leadership team, following the appointment of three high-profile entrepreneurs, Matthias Oertle, Marcel Frei and Subhasis Roy.
PharmaTimes
PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.